Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

By Global News Feed

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, to receive gross proceeds of approximately $6.0 million.

Continue reading here:
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

By Global News Feed

THE WOODLANDS, Texas, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

Read the original post:
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

By Global News Feed

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, the KOLs will lend their expertise and support to guide the education and clinical advancement efforts of the Human Acellular VesselTM (HAV) and help identify opportunities to advance the Company's early stage complex tissue constructs pipeline and platform.

View original post here:
Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

By Global News Feed

The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations

Read the original here:
Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

Lui Franciosi Tracking Published Fall Numbers of Seniors During this COVID-19 Pandemic

By Global News Feed

VANCOUVER, British Columbia, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. is currently tracking the number of falls involving seniors and that have been reported in the public domain during this COVID-19 pandemic. In particular, government sites such as the Canadian Institute for Health Information, online media reports and survey portals from various countries are being searched to determine these numbers as well as the nature and location of the falls in designated senior housing such as long term care, assisted living and independent living. Lui Franciosi states, “During this pandemic, seniors have likely not had the same level of exercise and therefore their body core strength is not as optimal to prevent injury. It is known that falls are the leading cause of injuries among seniors, accounting for 61 per cent of injury-related deaths and 81 per cent of injury-related hospitalizations in Canada. There are close to 5,000 deaths each year linked to seniors’ falls and nearly 100,000 hospitalizations.” The aim of this work is to better understand how many of these falls are actually predictable and whether an algorithm could be developed to help healthcare staff and families prevent falls, especially in frequent fallers.

View post:
Lui Franciosi Tracking Published Fall Numbers of Seniors During this COVID-19 Pandemic

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 109,250 shares of Baudax Bio’s common stock and restricted stock units covering 31,900 shares of Baudax Bio’s common stock to 14 newly-hired employees, with a grant date of December 29, 2021. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

Link:
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

→←